Public Market Listing
Live quotes, historical charts, and market capitalization for Knight Therapeutics are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | dopamine precursorSmall molecule | Parkinson's Disease | |
fostamatinib(Tavalisse) | Approved | Spleen tyrosine kinase (Syk)Small molecule | Immune Thrombocytopenia |
| Approved | EGFR/HER2Small molecule | Non-Small Cell Lung CancerBreast Cancer HER2-Positive Breast Cancer | |
| Approved | Mu-opioid receptor and norepinephrine transporter (NET)Small molecule | Diabetic Peripheral Neuropathic PainNeuropathic Pain Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain | |
| Approved | NHE3 (sodium/hydrogen exchanger isoform 3)Small molecule | Irritable Bowel Syndrome Irritable Bowel Syndrome with Constipation | |
viloxazine(Qelbree) | Approved | norepinephrine transporterSmall molecule | Attention Deficit Hyperactivity Disorder |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.